23 citations
,
November 2015 in “Phytotherapy Research” Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.
56 citations
,
November 1993 in “Journal of The American Academy of Dermatology” Capsaicin cream quickly relieved itching in two patients with brachioradial pruritus.
9 citations
,
July 2022 in “EMBO molecular medicine” Blocking certain immune signals can reduce skin damage from radiation therapy.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
April 2026 in “bioRxiv (Cold Spring Harbor Laboratory)” A new microneedle patch significantly improves melanoma treatment by using a special material to activate cancer-fighting drugs and disrupt cancer cells.
April 2018 in “Journal of Investigative Dermatology” BMP signaling is important for skin color, affecting melanin production, pigment spread, and cell movement.
December 2025 in “International Journal of Surgery” GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.
4 citations
,
October 2021 in “Scientific Reports” NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.
1 citations
,
April 2010 in “Cancer Research” WYE-130600 may cause skin thickening and irritation.
1 citations
,
May 2024 in “Human Genomics” Polygenic risk scores can predict the risk and outcomes of benign prostatic hyperplasia.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
2 citations
,
February 2004 in “Biopolymers” 4-(4-Phenoxybenzoyl)benzoic acid derivatives can both increase and decrease certain types of reactive oxygen species, and may be relevant to hair loss.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
August 2025 in “Skin Research and Technology”
December 2022 in “Otorhinolaryngology, Head and Neck Pathology.” Using PBMT and Respiro Mirtol forte after septoplasty reduces pain and inflammation.
26 citations
,
September 2024 in “Perspectives in Clinical Research” Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.
2 citations
,
June 2020 in “Dermatology and therapy” Narrowband-UVB phototherapy successfully treated a rare case of Graham Little-Piccardi-Lassueur syndrome.
4 citations
,
September 2017 in “Dermatologic surgery” The combination therapy improved skin pigmentation.
76 citations
,
July 2019 in “Scientific Reports” Baicalin nanocapsules greatly enhance its anticancer effects on breast cancer cells.
2 citations
,
February 2023 in “Urology” IsoPSA test works accurately even if patients take certain prostate medications.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
3 citations
,
April 2022 in “Research Square (Research Square)” PBX1 reduces aging and cell death in stem cells by boosting SIRT1 and lowering PARP1.
3 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Biological therapy boosts the immune system to effectively fight melanoma.
April 2023 in “Journal of Investigative Dermatology” In-person laser treatments help hair growth in androgenetic alopecia.
10 citations
,
May 2016 in “Journal of Dermatological Science” PDGF-BB helps young melanocytes grow but stops mature ones from growing, and it makes melanocytes more specialized.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.